ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

LIXT Lixte Biotechnology Holdings Inc

2.82
-0.0621 (-2.15%)
May 03 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Lixte Biotechnology Holdings Inc LIXT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0621 -2.15% 2.82 19:00:00
Open Price Low Price High Price Close Price Previous Close
3.00 2.8735 3.002 2.89 2.8821
more quote information »

Recent News

Date Time Source Heading
4/24/202414:25APSMixed Shelf Filing Gives Micro Cap Delayed Boost
3/27/202414:35APSBiotech Steals The Show Following Pre-Clinical Data..
3/27/202407:30GLOBENEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD..
3/21/202407:30GLOBELIXTE Provides Update on Progress with LB-100 as a PP2A..
2/27/202415:59EDGAR2Form 8-K - Current report
2/27/202407:30GLOBEProfessor René Bernards to Present New Pre-Clinical Data on..
2/26/202409:48EDGAR2Form 8-K - Current report
2/26/202407:30GLOBELIXTE Biotechnology Enters into Exclusive Immune Oncology..
1/29/202407:30GLOBEFirst Patient Dosed with LIXTE’s LB-100 and GSK’s..
11/28/202316:21EDGAR2Form 8-K - Current report
11/13/202313:28EDGAR2Form 8-K - Current report
11/13/202307:30GLOBELIXTE Biotechnology Provides Update on Clinical Progress and..
11/09/202316:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/17/202316:27EDGAR2Form 8-K - Current report
10/16/202313:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/16/202307:30GLOBELIXTE, Netherlands Cancer Institute, and Oncode Institute to..
10/10/202314:55EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/10/202314:47EDGAR2Form DEF 14A - Other definitive proxy statements
10/09/202307:30GLOBELIXTE Biotechnology Holdings Announces the Passing of its..
10/05/202319:39EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
10/05/202319:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/04/202317:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/29/202315:05EDGAR2Form PRE 14A - Other preliminary proxy statements
9/27/202305:15EDGAR2Form 8-K - Current report
9/27/202305:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/26/202307:30GLOBELIXTE Appoints Bas van der Baan as President and Chief..
9/20/202310:20EDGAR2Form 8-K - Current report
9/20/202307:30GLOBELIXTE Biotechnology Announces a Supported Collaborative..
8/11/202315:20EDGAR2Form S-3 - Registration statement under Securities Act of..
8/09/202307:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
7/21/202315:05EDGAR2Form 8-K - Current report
7/20/202315:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
7/20/202315:05GLOBELIXTE Biotechnology Announces Closing of $3.5 Million..
7/20/202310:45EDGAR2Form 8-K - Current report
7/18/202307:00GLOBELIXTE Biotechnology Announces Pricing of $3.5 Million..
7/17/202307:30GLOBEPreclinical Results of LIXTE Biotechnology’s Collaboration..
7/07/202313:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/07/202309:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/07/202309:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/07/202309:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
6/23/202307:30GLOBELIXTE Biotechnology Holdings, Inc. Regains Compliance with..
6/07/202307:30GLOBELIXTE Biotechnology and the Spanish Sarcoma Group Enroll..
6/02/202311:30GLOBELIXTE Biotechnology Holdings, Inc. Announces 1-for-10..
5/30/202307:30GLOBERecently Published Independent Research Reveals New..

Your Recent History

Delayed Upgrade Clock